Aisling Capital Management LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Aisling Capital Management LP reported 14 stock positions worth $471.6 million. Its top holding was Bridgebio Pharma (BBIO) at 72.5% of the portfolio, followed by Monte Rosa Therapeutics (GLUE, 8.0%) and Syndax Pharmaceuticals (SNDX, 6.1%). Compared with Q1 2026, it opened 1 new position and reduced 1. The biggest buy was a new position in VTV Therapeutics Class A (VTVT) and the biggest sale Bridgebio Pharma (BBIO, shares −10%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $471.6M (Q2 2026)
- SEC Filing
- 0001766721-26-000003 ↗ filed Aug 13, 2026
Holdings Value
Holdings 14 stocks · $471.6M
| BBIO Bridgebio Pharma Inc. | 72.48% | 4,589,611 | $341.8M | Reduce -9.8% |
| GLUE Monte Rosa Therapeutics Inc. | 7.98% | 1,555,664 | $37.6M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 6.10% | 1,316,806 | $28.8M | No change |
| CMPS Compass Pathways PLC | 4.30% | 1,432,336 | $20.3M | No change |
| BCAX Bicara Therapeutics Inc. | 3.58% | 568,919 | $16.9M | No change |
| BBOT Bridgebio Oncology Therapeut | 1.64% | 1,018,018 | $7.8M | No change |
| SRRK Scholar Rock Holding Corp. | 0.90% | 77,031 | $4.2M | No change |
| URGN Urogen Pharma Ltd. | 0.84% | 108,000 | $4.0M | No change |
| BMEA Biomea Fusion Inc. | 0.64% | 2,048,757 | $3.0M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.49% | 434,455 | $2.3M | No change |
| EPRX Eupraxia Pharmaceuticals Inc. | 0.46% | 325,000 | $2.1M | No change |
| VTVT VTV Therapeutics Inc. Class A | 0.40% | 50,000 | $1.9M | New |
| MRKR Marker Therapeutics Inc. | 0.10% | 325,370 | $478K | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.09% | 88,607 | $404K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| BBIO Bridgebio Pharma Inc. | Reduce -9.8% | 72.48% | −6.87 |
Portfolio Buys Q1 2026 → Q2 2026
| VTVT VTV Therapeutics Inc. Class A | New | 0.40% | +0.40 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |